Compare Johnson & Johnson (JNJ) vs Newmont Corporation (NEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Newmont Corporation — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Newmont Corporation trades at $117.84 (market cap $121.75B). The key difference: Johnson & Johnson is far larger — about 5.1× Newmont Corporation's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Newmont Corporation for 58 Days on average.
| JNJ | NEM | |
|---|---|---|
Market Cap | $618.09B | $121.75B |
Volume | 6,050,983 | 5,421,125 |
Sector | Health | Basic Materials |
52-Week High | $278.43 | $135.14 |
52-Week Low | $186.00 | $78.63 |
Typical Hold Time | 129 Days | 58 Days |
Enterprise Value | $646.37B | $118.34B |
Dividend Yield | 2.09% | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 28.45% net profit margin and consistent revenue growth to $94.19B in 2025. Analyst consensus remains positive with a $286.53 price target, though technical indicators show resistance at $258 and support at $253. Recent news highlights pipeline strength including Icotyde's $4.5B peak sales potential (Bank of America, 2026-09-29).
JNJ presents a compelling long-term investment with diversified healthcare exposure and dividend stability, though near-term technical weakness and patent cliff concerns warrant caution. The 52.5% buy rating from analysts reflects confidence in innovation pipeline, while debt-to-asset ratio increase to 24.06% merits monitoring. Upside potential exists if Q3 earnings beat expectations on October 13.
Newmont Corporation (NEM) trades at $115.55, up 1.77% with strong fundamental performance including record free cash flow of $5.3B in H1 2026 and three consecutive earnings beats. The stock shows bearish technical signals despite solid valuation metrics with P/E of 14.57 and ROE of 25.53%. Recent news highlights operational improvements and gold price support driving per-share growth initiatives.
NEM presents a compelling value opportunity with strong analyst consensus (75.68% buy rating) and $136.83 price target representing 18% upside. Key risks include gold price volatility and execution of growth projects, but robust cash flow generation and improving margins support long-term shareholder value creation in the current gold market environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
